ROCKVILLE, MD and SHENZHEN, CHINA, May 14, 2024—HighTide Therapeutics, Inc. , a globally integrated biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for metabolic and digestive diseases, announced toda
May 14, 2024
Learn More
The FII PRIORITY Asia Summit is taking place in Hong Kong. Dr. Liping Liu, Founder and CEO of HighTide Therapeutics, Inc. (HighTide) was invited to present at the summit on the topic of How to Upgrade the Human-tech Interface?.
December 08, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, November 2, 2023—HighTide Therapeutics, Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for metabolic and digestive diseases
November 02, 2023
Learn More
HighTide Therapeutics, Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic and digestive diseases, today announces that the company’s founder and CEO,
October 25, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, October 20, 2023— HighTide Therapeutics, Inc. (HighTide), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic
October 20, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, October 11, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic and digestive diseases
October 12, 2023
Learn More
We will contact you as soon as possible
© 2024 HighTide Therapeutics, Inc.